Description

Cencora, Inc.: Advancements in Generics and Fee-for-Service Models

Cencora has reported a strong fiscal 2024 third-quarter performance, with significant year-over-year growth in revenue and adjusted diluted EPS, which increased by 11% and 14%, respectively. The company’s revenue for the quarter amounted to over $74 billion, and the adjusted diluted EPS reached $3.34. This performance reflects Cencora’s effective execution against its pharmaceutical-centric strategy, leveraging its global leadership position in healthcare.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!